Clinical Trials

Inclusion Criteria:

• Male or female ≥ 18 years.
• Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures.
• Histologically or cytologically confirmed advanced solid tumors or lymphoma
• Measurable or evaluable disease per RECIST v1.1.
• ECOG performance status 0 or 1.
• Life expectancy ≥ 3 months.
• Adequate hepatic function.
• Calculated creatinine clearance (CrCL) > 50 mL/min (Cockroft-Gault Equation).
• Adequate Hematological function.
• Prothrombin time, international normalized ratio or activated partial thromboplastin time < 1.5 × ULN.
• Recovery, to Grade 0-1, from adverse events related to prior anticancer therapy.

Exclusion Criteria:

• Prior therapy with anti PD-L1/TGF?R? targeting treatment.
• Symptomatic primary central nervous system (CNS) tumor of CNS metastases.
• Uncontrolled hypertension.
• Significant thrombotic or hemorrhagic events.
• Prior CAR-T therapy
• Severe cardiovascular disease.
• Active infection requiring therapy
• Active HIV, hepatitis B or hepatitis C virus.
• Active tuberculosis.
• Anticancer therapy or radiation therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to study entry.
• Pregnant or breast-feeding females.
• Active or history of autoimmune disease or inflammatory disorders.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/27/22. Questions regarding updates should be directed to the study team contact.